At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
COLL Collegium Pharmaceutical
Market Closed 09-27 16:00:00 EDT
38.26
-0.21
-0.55%
盘后38.26
+0.000.00%
17:47 EDT
High39.08
Low38.18
Vol277.10K
Open39.00
D1 Closing38.47
Amplitude2.34%
Mkt Cap1.23B
Tradable Cap1.13B
Total Shares32.21M
T/O10.67M
T/O Rate0.94%
Tradable Shares29.49M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%?
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.